论文部分内容阅读
一般的头孢菌素渗透到脑脊液中的量很少,因此不考虑作为治疗细菌性脑膜炎的首选药物。氨噻肟头孢菌素(HR756)是新的头孢菌素之一。13例曾用其它抗菌素治疗未愈或具有对有效抗菌素耐药的致病菌的儿童脑膜炎(由流感嗜血杆菌、B族β—溶血性链球菌、肺炎链球菌、表皮葡萄球菌、脑膜炎奈瑟菌,大肠杆菌、绿脓杆菌所致),作者用静脉注射HR756治疗,其结果9例治愈;1例感染(由不同致病菌引起)复发,经又一疗程HR756治疗获愈;1例死亡(脑脊液无菌);1例由于潛在性疾病(星形细胞
The amount of cephalosporins commonly infiltrated into cerebrospinal fluid is small and therefore not considered as the drug of choice for the treatment of bacterial meningitis. Cefotaxime (HR756) is one of the new cephalosporins. Thirteen children with meningitis (consisting of Haemophilus influenzae, Group B β-hemolytic streptococcus, Streptococcus pneumoniae, Staphylococcus epidermidis, meningitis Neisseria, Escherichia coli, Pseudomonas aeruginosa caused by), the authors treated with intravenous HR756 treatment, the results of 9 cases of cure; 1 case of infection (caused by different pathogenic bacteria) recurrence, after a course of treatment HR756 treatment was cured; 1 Death (cerebrospinal fluid sterile); 1 case due to underlying disease (astrocytes